Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Apostolia Maria Tsimberidou, Tracey Waddelow, Hagop M. Kantarjian, Maher Albitar, Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.

Original languageEnglish (US)
Pages (from-to)375-380
Number of pages6
JournalLeukemia Research
Volume27
Issue number5
DOIs
StatePublished - May 1 2003

Keywords

  • Enbrel
  • Multiple myeloma
  • Refractory
  • TNFα

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment'. Together they form a unique fingerprint.

  • Cite this